Dan Gooding, chief executive of Nuformix (LON:NFX), caught up with Proactive London's Andrew Scott soon after raising £1.25mln to help advance its pipeline of drugs.
Gooding says the fundraise strengthens its position as negotiations continue in Asia for its NXP2 asset.